Rosenblum Silverman Sutton S F Inc Aclaris Therapeutics, Inc. Call Options Transaction History
Rosenblum Silverman Sutton S F Inc
- $345 Million
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACRS
# of Institutions
102Shares Held
53.5MCall Options Held
51KPut Options Held
31.6K-
Bml Capital Management, LLC Zionsville, IN9.4MShares$10.8 Million7.8% of portfolio
-
Black Rock Inc. New York, NY5.2MShares$5.98 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.93MShares$5.67 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.28MShares$3.78 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.27MShares$3.76 Million0.0% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $76.7M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...